$CRSP
CRISPR Therapeutics AG

2021 Q1 Form 10-Q Financial Statement

#000156459021020902 Filed on April 27, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $539.0K $157.0K
YoY Change 243.31% -52.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.50M $19.60M
YoY Change 25.0% 31.54%
% of Gross Profit
Research & Development $70.62M $54.19M
YoY Change 30.31% 60.23%
% of Gross Profit
Depreciation & Amortization $2.715M $2.091M
YoY Change 29.84% 157.51%
% of Gross Profit
Operating Expenses $115.1M $73.74M
YoY Change 56.06% 51.26%
Operating Profit -$114.5M -$73.59M
YoY Change 55.66% 51.96%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $1.955M $4.232M
YoY Change -53.8% 4132.0%
Pretax Income -$112.6M -$69.35M
YoY Change 62.34% 43.52%
Income Tax $600.0K $400.0K
% Of Pretax Income
Net Earnings -$113.2M -$69.73M
YoY Change 62.29% 44.05%
Net Earnings / Revenue -20994.99% -44414.65%
Basic Earnings Per Share -$1.51 -$1.15
Diluted Earnings Per Share -$1.51 -$1.15
COMMON SHARES
Basic Shares Outstanding 75.01M 60.85M
Diluted Shares Outstanding 75.01M 60.85M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.620B $889.7M
YoY Change 82.11% 103.36%
Cash & Equivalents $1.126B $889.7M
Short-Term Investments $494.2M
Other Short-Term Assets $26.00M $14.50M
YoY Change 79.31% 21.85%
Inventory
Prepaid Expenses
Receivables $200.0K $25.10M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.832B $929.3M
YoY Change 97.18% 106.6%
LONG-TERM ASSETS
Property, Plant & Equipment $51.91M $31.77M
YoY Change 63.39% 68.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.30M $662.0K
YoY Change 3419.64% -82.58%
Total Long-Term Assets $125.5M $78.00M
YoY Change 60.9% 62.15%
TOTAL ASSETS
Total Short-Term Assets $1.832B $929.3M
Total Long-Term Assets $125.5M $78.00M
Total Assets $1.958B $1.007B
YoY Change 94.37% 102.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.10M $11.28M
YoY Change 16.17% 58.83%
Accrued Expenses $49.86M $21.92M
YoY Change 127.44% 6.43%
Deferred Revenue $803.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $83.10M $55.09M
YoY Change 50.86% 93.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $69.30M $11.95M
YoY Change 479.87% -86.68%
Total Long-Term Liabilities $69.30M $11.95M
YoY Change 479.87% -86.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $83.10M $55.09M
Total Long-Term Liabilities $69.30M $11.95M
Total Liabilities $152.4M $121.2M
YoY Change 25.74% 2.63%
SHAREHOLDERS EQUITY
Retained Earnings -$294.4M
YoY Change
Common Stock $1.181B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K
YoY Change
Treasury Stock Shares $232.4K
Shareholders Equity $1.805B $886.1M
YoY Change
Total Liabilities & Shareholders Equity $1.958B $1.007B
YoY Change 94.37% 102.32%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$113.2M -$69.73M
YoY Change 62.29% 44.05%
Depreciation, Depletion And Amortization $2.715M $2.091M
YoY Change 29.84% 157.51%
Cash From Operating Activities -$100.7M -$52.18M
YoY Change 92.93% 19.29%
INVESTING ACTIVITIES
Capital Expenditures $7.024M $2.991M
YoY Change 134.84% 172.65%
Acquisitions
YoY Change
Other Investing Activities -$160.9M
YoY Change
Cash From Investing Activities -$167.9M -$2.991M
YoY Change 5513.44% 172.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $214.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 226.0M 1.132M
YoY Change 19863.87% -95.6%
NET CHANGE
Cash From Operating Activities -100.7M -52.18M
Cash From Investing Activities -167.9M -2.991M
Cash From Financing Activities 226.0M 1.132M
Net Change In Cash -42.57M -54.06M
YoY Change -21.26% 183.03%
FREE CASH FLOW
Cash From Operating Activities -$100.7M -$52.18M
Capital Expenditures $7.024M $2.991M
Free Cash Flow -$107.7M -$55.17M
YoY Change 95.21% 23.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
521713000
CY2019Q4 crsp Rental Payments Period Under Lease Arrangement
RentalPaymentsPeriodUnderLeaseArrangement
P5Y
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
539000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
115082000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-114543000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-73586000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1955000
CY2020Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4232000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74110160
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73914844
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-69731000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-25000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-383000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113541000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69756000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75005187
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60847683
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.15
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75005187
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60847683
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
939425000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1388000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14151000
CY2020Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
889000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-25000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-69731000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
886097000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222175000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9784000
CY2021Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
751000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-113163000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-69731000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2715000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2091000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
22092000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14151000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2064000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-890000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25018000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5068000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-29659000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5770000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2496000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-539000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-157000
CY2021Q1 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
778000
CY2020Q1 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
37000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3766000
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1601000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1805498000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-100663000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52175000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7024000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2991000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
323975000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
163101000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-167898000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2991000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
214592000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11399000
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1132000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225991000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1132000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-25000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42565000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1142903000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
894753000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8847000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1340000
CY2021Q1 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
2868000
CY2020Q1 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
39000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1126059000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
889712000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16844000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5041000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1142903000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
894753000
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. <span style="color:#212529;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
494200000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
395100000
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
631890000
CY2021Q1 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
680144000
CY2021Q1 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
2000
CY2021Q1 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
631889000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
680657000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
552000
CY2021Q1 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1312547000
CY2021Q1 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
40000
CY2021Q1 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
554000
CY2021Q1 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1312033000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
773560000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
24000
CY2020Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
773537000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
521820000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
158000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
521713000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1295380000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
52000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
182000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1295250000
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
473700000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
280300000
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
400000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2021Q1 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
75794000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63335000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23881000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21175000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51913000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42160000
CY2021Q1 us-gaap Depreciation
Depreciation
2700000
CY2020Q1 us-gaap Depreciation
Depreciation
2100000
CY2021Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6784000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11565000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22402000
CY2021Q1 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
22034000
CY2020Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
21684000
CY2021Q1 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
930000
CY2020Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
1401000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1874000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1670000
CY2021Q1 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
5229000
CY2020Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3625000
CY2021Q1 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
6869000
CY2020Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
2835000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1363000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49864000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53782000
CY2020Q3 crsp Rental Payments Period Under Lease Arrangement
RentalPaymentsPeriodUnderLeaseArrangement
P152M
CY2021Q1 crsp Prepaid Expenses And Other Current Assets Fair Value Disclosure
PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure
2565000
CY2021Q1 us-gaap Property Plant And Equipment Fair Value Disclosure
PropertyPlantAndEquipmentFairValueDisclosure
9340000
CY2021Q1 crsp Operating Lease Assets Fair Value Disclosure
OperatingLeaseAssetsFairValueDisclosure
11003000
CY2021Q1 crsp Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
1226000
CY2021Q1 crsp Accrued Expenses And Other Current Liabilities Fair Value Disclosure
AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure
3915000
CY2021Q1 crsp Operating Lease Liabilities Fair Value Disclosure
OperatingLeaseLiabilitiesFairValueDisclosure
11003000
CY2021Q1 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
16000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q1 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
80321227
CY2020Q4 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
75133951
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22092000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14151000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8101980
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.44
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
882558
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
139.05
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
342471
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
33.12
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
69404
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
43.31
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8572663
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.76
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3962897
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.48
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8572663
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
52.76
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
191300000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9635636
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9462375
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000

Files In Submission

Name View Source Status
0001564590-21-020902-index-headers.html Edgar Link pending
0001564590-21-020902-index.html Edgar Link pending
0001564590-21-020902.txt Edgar Link pending
0001564590-21-020902-xbrl.zip Edgar Link pending
crsp-10q_20210331.htm Edgar Link pending
crsp-10q_20210331_htm.xml Edgar Link completed
crsp-20210331.xsd Edgar Link pending
crsp-20210331_cal.xml Edgar Link unprocessable
crsp-20210331_def.xml Edgar Link unprocessable
crsp-20210331_lab.xml Edgar Link unprocessable
crsp-20210331_pre.xml Edgar Link unprocessable
crsp-ex101_13.htm Edgar Link pending
crsp-ex102_12.htm Edgar Link pending
crsp-ex103_11.htm Edgar Link pending
crsp-ex104_533.htm Edgar Link pending
crsp-ex311_8.htm Edgar Link pending
crsp-ex312_7.htm Edgar Link pending
crsp-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending